209 related articles for article (PubMed ID: 29607586)
1. Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting.
Lee B; Tran B; Hsu AL; Taylor GR; Fox SB; Fellowes A; Marquis R; Mooi J; Desai J; Doig K; Ekert P; Gaff C; Herath D; Hamilton A; James P; Roberts A; Snyder R; Waring P; McArthur G
Intern Med J; 2018 Jul; 48(7):786-794. PubMed ID: 29607586
[TBL] [Abstract][Full Text] [Related]
2. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
[TBL] [Abstract][Full Text] [Related]
3. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
[TBL] [Abstract][Full Text] [Related]
4. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
[TBL] [Abstract][Full Text] [Related]
5. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
[TBL] [Abstract][Full Text] [Related]
6. Personalized genomic analyses for cancer mutation discovery and interpretation.
Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
[TBL] [Abstract][Full Text] [Related]
7. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
[TBL] [Abstract][Full Text] [Related]
8. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
9. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
11. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
[TBL] [Abstract][Full Text] [Related]
12. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
[TBL] [Abstract][Full Text] [Related]
13. Preliminary whole-exome sequencing reveals mutations that imply common tumorigenicity pathways in multiple endocrine neoplasia type 1 patients.
Romero Arenas MA; Fowler RG; San Lucas FA; Shen J; Rich TA; Grubbs EG; Lee JE; Scheet P; Perrier ND; Zhao H
Surgery; 2014 Dec; 156(6):1351-7; discussion 1357-8. PubMed ID: 25456907
[TBL] [Abstract][Full Text] [Related]
14. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.
Ghazani AA; Oliver NM; St Pierre JP; Garofalo A; Rainville IR; Hiller E; Treacy DJ; Rojas-Rudilla V; Wood S; Bair E; Parello M; Huang F; Giannakis M; Wilson FH; Stover EH; Corsello SM; Nguyen T; Rana HQ; Church AJ; Lowenstein C; Cibulskis C; Amin-Mansour A; Heng J; Brais L; Santos A; Bauer P; Waldron A; Lo P; Gorman M; Lydon CA; Welch M; McNamara P; Gabriel S; Sholl LM; Lindeman NI; Garber JE; Joffe S; Van Allen EM; Gray SW; Ja Nne PA; Garraway LA; Wagle N
Genet Med; 2017 Jul; 19(7):787-795. PubMed ID: 28125075
[TBL] [Abstract][Full Text] [Related]
15. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
16. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
17. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
Worst BC; van Tilburg CM; Balasubramanian GP; Fiesel P; Witt R; Freitag A; Boudalil M; Previti C; Wolf S; Schmidt S; Chotewutmontri S; Bewerunge-Hudler M; Schick M; Schlesner M; Hutter B; Taylor L; Borst T; Sutter C; Bartram CR; Milde T; Pfaff E; Kulozik AE; von Stackelberg A; Meisel R; Borkhardt A; Reinhardt D; Klusmann JH; Fleischhack G; Tippelt S; Dirksen U; Jürgens H; Kramm CM; von Bueren AO; Westermann F; Fischer M; Burkhardt B; Wößmann W; Nathrath M; Bielack SS; Frühwald MC; Fulda S; Klingebiel T; Koscielniak E; Schwab M; Tremmel R; Driever PH; Schulte JH; Brors B; von Deimling A; Lichter P; Eggert A; Capper D; Pfister SM; Jones DT; Witt O
Eur J Cancer; 2016 Sep; 65():91-101. PubMed ID: 27479119
[TBL] [Abstract][Full Text] [Related]
18. The Rise and Rise of Exome Sequencing.
Ku CS; Cooper DN; Patrinos GP
Public Health Genomics; 2016; 19(6):315-324. PubMed ID: 27898412
[TBL] [Abstract][Full Text] [Related]
19. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
Postel-Vinay S; Boursin Y; Massard C; Hollebecque A; Ileana E; Chiron M; Jung J; Lee JS; Balogh Z; Adam J; Vielh P; Angevin E; Lacroix L; Soria JC
Ann Oncol; 2016 Feb; 27(2):344-52. PubMed ID: 26598538
[TBL] [Abstract][Full Text] [Related]
20. Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies.
Waldmüller S; Schroeder C; Sturm M; Scheffold T; Imbrich K; Junker S; Frische C; Hofbeck M; Bauer P; Bonin M; Gawaz M; Gramlich M
Mol Cell Probes; 2015 Oct; 29(5):308-14. PubMed ID: 25979592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
